Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ZimVie Inc ( (ZIMV) ) has issued an update.
On October 10, 2025, ZimVie Inc. announced that its stockholders approved the acquisition by an affiliate of ARCHIMED during a special meeting. The merger, which will result in ZimVie becoming a wholly owned subsidiary of ARCHIMED, is expected to close on October 20, 2025, leading to the delisting of ZimVie’s common stock from the Nasdaq Global Select Market.
The most recent analyst rating on (ZIMV) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on ZimVie Inc stock, see the ZIMV Stock Forecast page.
Spark’s Take on ZIMV Stock
According to Spark, TipRanks’ AI Analyst, ZIMV is a Neutral.
ZimVie’s overall stock score reflects a mix of challenges and opportunities. The acquisition by ARCHIMED at a premium is a major positive factor, providing potential future stability and growth. However, ongoing financial performance issues, such as declining revenue and profitability challenges, weigh down the score. Technical indicators show bullish momentum, but caution is advised due to overbought signals. Valuation remains a concern due to negative earnings.
To see Spark’s full report on ZIMV stock, click here.
More about ZimVie Inc
ZimVie is a global leader in the life sciences sector, focusing on dental implants. The company develops, manufactures, and delivers a comprehensive range of products and solutions for dental tooth replacement and restoration procedures. Headquartered in Palm Beach Gardens, Florida, ZimVie aims to enhance smiles, function, and confidence through its offerings, including dental implants, biomaterials, and digital workflow solutions.
Average Trading Volume: 703,765
Technical Sentiment Signal: Buy
Current Market Cap: $534M
Learn more about ZIMV stock on TipRanks’ Stock Analysis page.